* Sonoma Pharmaceuticals Inc is expected to show a rise in quarterly revenue when it reports results on February 6 (estimated) for the period ending December 31 2024
* The Boulder Colorado-based company is expected to report a 39.9% increase in revenue to $4.39 million from $3.14 million a year ago, according to the estimate from one analyst, based on LSEG data.
* LSEG's mean analyst estimate for Sonoma Pharmaceuticals Inc is for a loss of 80 cents per share.
* The one available analyst rating on the shares is "strong buy".
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Sonoma Pharmaceuticals Inc is $30.00, above its last closing price of $2.92.
This summary was machine generated November 8 at 23:25 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments